89Zr‐Labeled DFO@Durvalumab‐HSA nanoparticles: In vitro potential for triple‐negative breast cancer

• DOI: 10.1002/ddr.22266
• Publication Date: 2024-10-04T05:30:02Z
• Authors: Fatma Yurt; Derya Özel; Şeyma Karagül; Ayça Tunçel; Kübra Durkan; Emin İlker Medine
• Keywords: Triple-negative breast cancer

This study presents the development and evaluation of a DFO@mAb-NP (DFO@Durvalumab-HSA-DTX nanoparticle) nanoplatform for imaging in triple-negative breast cancer (TNBC). The demonstrated significant changes postconjugation with DFO, evidenced by increased particle size from 178.1 ± 5 nm to 311 26 zeta potential alteration -31.9 3 mV -40.5 0.8 mV. Fourier-transform infrared spectroscopy ultraviolet spectral analyses confirmed successful DFO conjugation, notable shifts peak wavelengths. High labeling efficiency was achieved